about
p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.cFos mediates cAMP-dependent generation of ROS and rescue of maturation program in retinoid-resistant acute promyelocytic leukemia cell line NB4-LR1.Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT.Telomeres and telomerase: Pharmacological targets for new anticancer strategies?Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias.Pro-survival role of p62 during granulocytic differentiation of acute myeloid leukemia cells.Telomerase regulation in hematological cancers: a matter of stemness?The telomere story or the triumph of an open-minded research.Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.cAMP-Dependent Protein Kinase A (PKA)-Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes.Activation of both protein kinase A (PKA) type I and PKA type II isozymes is required for retinoid-induced maturation of acute promyelocytic leukemia cells.Antitumor trans-N-heterocyclic carbene-amine-Pt(II) complexes: synthesis of dinuclear species and exploratory investigations of DNA binding and cytotoxicity mechanisms.Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant.hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide.Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance.Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation.Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives.[Cell death signalling: recent advances and therapeutic application].[Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells.Nuclear translocation of a leukocyte elastase Inhibitor/Elastase complex during staurosporine-induced apoptosis: role in the generation of nuclear L-DNase II activityEctopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiationTelomeres and telomerase: from basic research to clinical applicationsImmunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross pathsPlatinum Complexes Can Bind to Telomeres by CoordinationComplex context-relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid (ATRA) in cancer therapy
P50
Q34486392-64C9ED33-8824-4093-9F76-E673AE8BF0EAQ34500276-D28770AA-F90B-4F1C-989C-28F26D29318CQ34933818-982780A5-DEA4-4018-BD00-56C7DB4D586BQ35004395-AAB1239C-7938-48E6-A809-F937D7778ECCQ35626186-91980763-BCAB-44E5-8B04-4BBCCBFC13C9Q36418055-29FDDA6F-F877-410D-B999-C997318DC53CQ36514241-FE5AC10E-3104-468D-9573-499D8D492EF0Q36997778-A4663A97-CC5F-47EC-991E-81A408FFAF35Q37472293-5E902623-FC03-41EA-BC0E-1325C7B904B1Q37680229-F79B97AA-89AD-4A6A-B827-935D49683754Q38754328-974627D0-CE4A-4DD9-BC97-B6A10C99B65BQ38826671-791930F8-6F8F-49DE-87B7-AE995C75F4F6Q38860739-E29FA596-DCFB-415C-B68E-7432DC969C72Q39186195-D70F0C9D-3892-42B7-8372-FDC985F06435Q39192049-3ECC273B-AA4E-46F5-AF60-9525CCE5BCE3Q39288424-0DE32015-6D33-40C8-9023-13299A46BA05Q39583692-EF18BFF9-231C-44D0-B83B-AE7E4D0EA2E7Q40315553-00919AF6-B882-416F-9171-C1C9A99D35C2Q40454080-A28A3FE1-7A0B-435B-A118-2AFCDB7FC589Q40522862-452FF9B8-FC60-49C7-8399-1CBB1C8DA676Q40608539-A5279EAB-E95B-46CC-94B9-F4933C4B7C3CQ40734744-843A6823-E4D6-4B87-AE93-E7EC0CFAD962Q41449232-6E4BEB59-CBA1-43C1-8C93-26FCE327C098Q53361093-78F22E1B-2FE6-4398-AA92-2551EEAB5FC7Q53939432-CF4F6A73-0650-45B5-B74C-25700DF2AD44Q54090921-2A8670EE-8F79-449D-83AF-7F504E4B2E68Q73329788-D2C7877F-CBD5-468C-BC09-313409C39684Q73347777-1D893E20-413E-4349-A6C5-E08394B0649EQ81554071-8FEADF15-BEC7-44EC-96FA-18DF9D32DE97Q83986260-099DD036-0BB9-49E2-A69D-88150ADABACCQ89411750-A8AE1221-57BB-42EF-85CC-676A0EB88002Q90840656-C8DEF19F-FED4-4116-8D9C-984FD5636199
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Evelyne Ségal-Bendirdjian
@ast
Evelyne Ségal-Bendirdjian
@en
Evelyne Ségal-Bendirdjian
@es
Evelyne Ségal-Bendirdjian
@sl
type
label
Evelyne Ségal-Bendirdjian
@ast
Evelyne Ségal-Bendirdjian
@en
Evelyne Ségal-Bendirdjian
@es
Evelyne Ségal-Bendirdjian
@sl
prefLabel
Evelyne Ségal-Bendirdjian
@ast
Evelyne Ségal-Bendirdjian
@en
Evelyne Ségal-Bendirdjian
@es
Evelyne Ségal-Bendirdjian
@sl
P106
P21
P31
P496
0000-0001-9813-4880